NCT06898671 Language Outcomes, Mechanisms, and Trajectories in Adults With and Without Developmental Language Disorder
| NCT ID | NCT06898671 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Iowa |
| Condition | Developmental Language Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2023-04-17 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2023-04-17 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators' overall objective is to characterize the long-term outcomes of Developmental Language Disorder (DLD) in adulthood and to identify specific cognitive mechanisms mediating these outcomes. To address their objectives, the investigators utilize a large, pre-existing dataset and participant pool from one of the most comprehensive examinations of DLD to date: the Iowa Longitudinal Study. The investigators will re-recruit subjects with DLD and with typical language from this historic cohort, who are now adults (30-35 years old). In Aim 1, the investigators will use measures from kindergarten through 10th grade and collect new outcome measures in adulthood to characterize the long-term outcomes of DLD. The investigators predict that adults with DLD will diverge from adults with TL in language skills that are more complex and higher-level language skills that are important for communication in the workplace. Further, the investigators predict a fanning effect: some children with DLD will "catch up" to their TL peers in adulthood, some will show evidence of a decline, and others will show stable trajectories. In Aim 2, the investigators measure real-time competition across written and spoken language using eye-tracking. According to speed of processing accounts adults with DLD may be slower than their TL peers to activate competitors and targets. According to working memory accounts adults with DLD will show sustained competitor activation. Further, the investigators predict that measures related to the dynamics of competition (speed of activation and timing of competitor suppression) will account for variation in language outcomes in adults.
Eligibility Criteria
Inclusion Criteria: * Adults with Developmental Language Disorder (DLD) and those with typical language (TL) between the ages of 28 and 40 years who participated in the Iowa Longitudinal Study(NIH-DC-19-90 \& P50 DC002746; IRB# 200106051, "Collaboration on Specific Language Impairment".) * Aged 30-35 * Normal or corrected to normal vision * Normal hearing Exclusion Criteria: * history of brain injury * history of neural developmental disabilities * not monolingual
Contact & Investigator
Stewart McCauley, PhD
PRINCIPAL INVESTIGATOR
University of Iowa
Frequently Asked Questions
Who can join the NCT06898671 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 35 Years, studying Developmental Language Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06898671 currently recruiting?
Yes, NCT06898671 is actively recruiting participants. Contact the research team at kristi-hendrickson@uiowa.edu for enrollment information.
Where is the NCT06898671 trial being conducted?
This trial is being conducted at Iowa City, United States.
Who is sponsoring the NCT06898671 clinical trial?
NCT06898671 is sponsored by University of Iowa. The principal investigator is Stewart McCauley, PhD at University of Iowa. The trial plans to enroll 400 participants.